Cliftonlarsonallen Wealth Advisors LLC Lowers Stake in Pfizer Inc. (NYSE:PFE)

Cliftonlarsonallen Wealth Advisors LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 16.1% in the 4th quarter, Holdings Channel reports. The fund owned 14,663 shares of the biopharmaceutical company’s stock after selling 2,823 shares during the quarter. Cliftonlarsonallen Wealth Advisors LLC’s holdings in Pfizer were worth $389,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Citizens Financial Group Inc. RI raised its holdings in shares of Pfizer by 63.5% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 200,310 shares of the biopharmaceutical company’s stock valued at $5,605,000 after buying an additional 77,780 shares in the last quarter. Wulff Hansen & CO. raised its stake in shares of Pfizer by 2,698.0% during the second quarter. Wulff Hansen & CO. now owns 269,000 shares of the biopharmaceutical company’s stock worth $7,527,000 after acquiring an additional 259,386 shares in the last quarter. Lmcg Investments LLC lifted its holdings in shares of Pfizer by 1.1% in the 2nd quarter. Lmcg Investments LLC now owns 51,777 shares of the biopharmaceutical company’s stock worth $1,449,000 after acquiring an additional 543 shares during the last quarter. Excalibur Management Corp boosted its stake in shares of Pfizer by 1.9% in the 2nd quarter. Excalibur Management Corp now owns 164,336 shares of the biopharmaceutical company’s stock valued at $4,598,000 after purchasing an additional 3,090 shares in the last quarter. Finally, Moors & Cabot Inc. grew its holdings in shares of Pfizer by 18.7% during the 2nd quarter. Moors & Cabot Inc. now owns 451,182 shares of the biopharmaceutical company’s stock valued at $12,624,000 after purchasing an additional 71,082 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Finally, Citigroup initiated coverage on shares of Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Up 0.7 %

Pfizer stock traded up $0.18 during trading hours on Wednesday, hitting $26.59. The stock had a trading volume of 1,870,942 shares, compared to its average volume of 29,812,969. The stock has a market capitalization of $150.69 billion, a P/E ratio of 35.93, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock’s 50-day moving average price is $26.13 and its 200-day moving average price is $28.03. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.17) EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.47%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 232.43%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.